和肽素与尿液浓缩能力可预测锂治疗患者的肾功能下降
该研究纳入98例接受锂治疗的双相障碍患者,于2012/2013年行去氨加压素试验测定最大尿液浓缩能力(MUCC),并检测血浆和肽素及尿液生物标志物。中位随访发现,基线eGFR、MUCC和和肽素与随访期间肾功能下降相关,和肽素与MUCC联合可预测未来肾功能下降。
要点
- 锂治疗患者中约51%存在轻度尿液浓缩能力受损(尿渗透压600-800 mOsmol/kg)。
- 基线eGFR、UPU、和肽素、KIM-1、HFABP和NGAL与MUCC独立相关。
- 基线和肽素与MUCC均与随访期间肾功能下降独立相关。
核心结论
- 多种生物标志物可用于评估最大尿液浓缩能力。
- 和肽素与MUCC均与未来肾功能下降相关,可作为预测指标。
研究设计与样本
- 前瞻性队列研究,纳入98例接受锂治疗的双相障碍患者,于2012/2013年入组。
- 93例患者有长期随访肾功能数据。
主要发现
- 校正年龄、性别和eGFR后,基线eGFR(St. β=0.44,P≤0.001)、UPU(St. β=0.34,P≤0.001)、和肽素(St. β=-0.23,P=0.02)、KIM-1(St. β=-0.23,P=0.02)、HFABP(St. β=-0.21,P=0.03)和NGAL(St. β=-0.25,P=0.02)与MUCC显著相关。
- 混合线性模型显示,基线eGFR(β=0.97,95%CI [0.88;1.06],P<0.001)、MUCC(β=0.05,95%CI [0.03;0.06],P<0.001)和和肽素(β=-7.10,95%CI [-10.9;-3.28],P<0.001)与随访期间肾功能相关。
临床怎么用
- 对于锂治疗患者,可考虑检测血浆和肽素和尿液浓缩能力以识别高危肾功能下降人群。
- 和肽素可能作为锂诱导的肾性尿崩症和未来肾功能下降的候选生物标志物。
局限性
- 样本量较小(98例),随访数据来自93例患者。
- 未报告随访时长及具体肾功能下降速率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: A common early side effect of lithium treatment in bipolar disorder is a reduced urine concentrating capacity possibly progressing to arginine vasopressin (AVP) resistance (AVP-R), also known as lithium-induced nephrogenic diabetes insipidus (Li-NDI). Long term lithium therapy can also lead to chronic kidney disease (CKD) with kidney function decline. Due to lack of markers to identify Li-NDI, it is often overseen even though prevalence and impact on quality of life are substantial. Moreover, the correlation between reduction of urine concentrating capacity and CKD remains unclear. This study aims to identify markers for Li-NDI and future kidney function decline. METHODS: 98 patients treated with lithium underwent a desmopressin (DDAVP) test to determine maximal urine concentrating capacity (MUCC) after inclusion in 2012/2013. Plasma copeptin, urine biomarkers AQP-2, NAG, KIM-1, HFABP, NGAL and urine-to-plasma urea ratio (UPU) were measured. Long term follow-up data of kidney function decline during lithium therapy was collected of 93 out of 98 patients. RESULTS: Fifty patients (51%) had an mildly impaired MUCC (urine osmolality 600-800 mOsmol/kg), 16 patients (16%) a moderately decreased MUCC (300-600 mOsm/kg) and 1 patient (1%) a severely impaired MUCC (<300 mOsm/kg). Baseline eGFR, UPU, copeptin, KIM-1, HFABP and NGAL were significantly associated with MUCC when corrected for age, sex and eGFR (when appropriate) (eGFR: St. β=0.44, P ≤ 0.001, UPU: St. β=0.34, P ≤ 0.001; copeptin: St. β=-0.23, P = 0.02; KIM-1: St. β=-0.23, P = 0.02, HFABP: St. β=-0.21, P = 0.03) NGAL: St. β=-0.25, P = 0.02). eGFR, MUCC and copeptin at baseline were associated with kidney function during follow-up using mixed linear model analysis (eGFR: β=0.97 95%CI [0.88;1.06], P < 0.001; MUCC: β=0.05 95%CI[0.03;0.06], P < 0.001 and copeptin:-β=7.10 95%CI[-10.9;-3.28], P < 0.001). CONCLUSION: Multiple biomarkers were identified to test for MUCC. Copeptin is particularly interesting as it was, together with MUCC, associated with future kidney function decline.
引用
- Zittema D, van der Aa M, Doornebal J, et al. Copeptin and urine concentrating capacity predict kidney function decline in lithium-treated patients. Nephrol Dial Transplant. 2026. PMID: 42847926. doi:10.1093/ndt/gfag219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。